Online inquiry

IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ785MR)

This product GTTS-WQ785MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets AXL gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001278599.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 558
UniProt ID M0R0W6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ785MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4396MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ1211MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ13478MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ379MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ287MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ2735MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ15826MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ3294MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ASN-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW